Beyond Air Receives FDA's Breakthrough Device Designation To LungFit GO To Treat Nontuberculous Mycobacterial Pulmonary Disease
Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve
Beyond Air's lung treatment device just got fast-track approval from the FDA, meaning doctors might be able to use it sooner to help patients with a serious lung infection. When a company gets this special designation, it shows the FDA thinks their product could really help people, which is a positive sign for the company's future.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.